Nautilus Biotechnology (NASDAQ:NAUT – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.02, FiscalAI reports. The business had revenue of $0.23 million for the quarter, compared to the consensus estimate of $0.21 million.
Nautilus Biotechnology Price Performance
NAUT stock opened at $2.44 on Tuesday. Nautilus Biotechnology has a 12 month low of $0.84 and a 12 month high of $4.31. The firm’s 50-day moving average is $1.42 and its 200 day moving average is $2.09. The company has a market capitalization of $310.49 million, a PE ratio of -5.42 and a beta of 0.73.
Wall Street Analyst Weigh In
NAUT has been the topic of a number of research reports. Leerink Partners initiated coverage on shares of Nautilus Biotechnology in a report on Wednesday, September 9th. They issued an “outperform” rating and a $4.00 target price on the stock. Zacks Research raised shares of Nautilus Biotechnology to a “hold” rating in a report on Wednesday, September 30th. Weiss Ratings lowered Nautilus Biotechnology from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, August 5th. Finally, Roth Capital started coverage on Nautilus Biotechnology in a research note on Tuesday, September 29th. They set a “buy” rating and a $3.50 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Nautilus Biotechnology presently has a consensus rating of “Moderate Buy” and an average target price of $3.83.
Check Out Our Latest Stock Analysis on Nautilus Biotechnology
About Nautilus Biotechnology
Nautilus Biotechnology, Inc is a biotechnology company developing technologies for large-scale protein analysis, also known as proteomics. Its goal is to enable researchers to identify and quantify proteins more comprehensively, helping advance drug discovery, biological research and the development of precision medicine.
The company’s principal offering is the Nautilus Proteome Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software.
Further Reading
- Five stocks we like better than Nautilus Biotechnology
- AST SpaceMobile Faces Launch Risks as SpaceX Raises the Competitive Stakes
- GXO Logistics Is Turning Warehouse Robots Into a Growth Strategy
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
